HYPERION DEFI, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
HYPERION DEFI, INC. (HYPD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.72% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-30
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-09-30 was 3.80%.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-09-30 was 2.95%, a 23.43% increase year-over-year.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-06-30 was 2.83%.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-09-30 was 2.39%.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.72%, a 0.00% change from fiscal 2023.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.72%.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 3.24%, a 35.56% increase from fiscal 2017.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.39%, a 30.60% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2024-12-31 | 4.72% 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 3.80% 10-Q · filed 2025-11-14 | 4.72% 10-Q · filed 2025-11-14 | ||
| 2023-12-31 | 4.72% 10-K · filed 2025-04-15 | |||
| 2018-12-31 | 3.24% 10-K · filed 2019-03-27 | |||
| 2018-09-30 | 2.95% 10-Q · filed 2018-11-13 | 2.95% 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | 2.83% 10-Q · filed 2018-08-14 | 2.83% 10-Q · filed 2018-08-14 | ||
| 2017-12-31 | 2.39% 10-K · filed 2019-03-27 | |||
| 2017-09-30 | 2.39% 10-Q · filed 2018-11-13 | 2.39% 10-Q · filed 2018-11-13 | ||
| 2016-12-31 | 1.83% 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |